Dome Gold Mines (DME) Q4 2024 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 TU earnings summary
13 Jun, 2025Executive summary
Continued progress on Sigatoka Feasibility Study and Environmental Impact Assessment, both key for mining lease application.
Three-year renewals for SPL1451 (Ono Island) and SPL1452 (Nadroga) approved, enabling ongoing exploration.
Directors visited Fiji, meeting with government officials and a potential customer for Sigatoka magnetite concentrate.
Financial highlights
$60K spent on exploration and related activities during the quarter, with $59K allocated to Sigatoka DFS program.
No expenditure on mining production or development activities in the quarter.
As of 30 June 2024, cash balance was $1K; $442K raised via share placement in July.
Outlook and guidance
Next phase of exploration at Ono Island will focus on the southern half with soil geochemistry and mapping.
Nadroga project to proceed with geophysical surveys to identify drill targets.
Sigatoka project advancing towards mining lease application, pending completion of feasibility and EIA reviews.
Latest events from Dome Gold Mines
- Sigatoka Feasibility Study advanced; $314K cash and 7 quarters of funding available.DME
Q1 2026 TU21 Dec 2025 - Sigatoka feasibility study advanced amid delays; strong cash and financing position maintained.DME
Q4 2025 TU5 Oct 2025 - Sigatoka project advances amid higher net loss and ongoing funding needs.DME
H2 202530 Sep 2025 - Sigatoka feasibility progresses, new Nadroga gold anomaly found, and funding remains strong.DME
Q3 2025 TU22 Jun 2025 - Net loss narrowed to $2.19M as Sigatoka project advanced, but going concern risk remains.DME
H2 202413 Jun 2025 - Sigatoka feasibility and EIA advanced; $1.12M raised, $303K cash, $4.56M loans undrawn.DME
Q1 2025 TU13 Jun 2025 - Losses persist as Dome Gold Mines advances Fiji projects and secures new funding.DME
H1 20256 Jun 2025 - Sigatoka feasibility advances and funding remains strong as Dome secures key project approvals.DME
Q2 2025 TU6 Jun 2025